Sign in Subscribe
Cancer research

Mitochondrial Genome Variants Linked to Glioma Grade and Survival

Strategic Insights

— 1 min read

Research conducted at the Memorial Sloan-Kettering Cancer Center in New York City has shed light on the relationship between mitochondrial genome variants and glioma grade, as well as patient survival in glioblastoma (GBM) patients. The study, which analyzed germline mtDNA sequencing for 388 patients with incident glioma, identified associations between mtDNA common variants, haplogroups, and gene variant burden in relation to glioma grade and tertiles of survival in GBM patients. While no mtDNA haplogroup was associated with glioma grade or patient survival in GBM, certain mtDNA variants were linked to lower-grade glioma risk, and others were associated with poorer or improved prognosis in GBM patients. However, these findings did not remain statistically significant after correction for multiple comparisons.

Key Takeaways:

  • The study analyzed germline mtDNA sequencing for 388 patients with incident glioma, including 300 Caucasians and 88 African Americans.
  • The research identified 1431 homoplasmic mtDNA variants, including 692 variants observed only in Caucasians, 474 only in African Americans, and 265 in both groups.
  • Certain mtDNA variants, such as m.3010G A, m.195T C, and m.16189T C, were linked to lower-grade glioma risk.
  • Other mtDNA variants, including m.1719G A, m.14766T C, m.16129G A, and m.204T C, were associated with a poorer prognosis in GBM patients.
  • A higher variant burden in MT-ND1 and MT-ND5 was associated with a better prognosis in GBM patients.
  • The study concluded that the results warrant further study in larger populations and investigation of biologic mechanisms linking mtDNA polymorphism to glioma grade and tumour survival.

Statistics:

  • 300 Caucasians and 88 African Americans were included in the study.
  • 1431 homoplasmic mtDNA variants were identified, including 692 variants observed only in Caucasians, 474 only in African Americans, and 265 in both groups.
  • 101 non-GBM and 283 GBM patients were analyzed.
  • The study estimated Odds Ratios (OR) and 95% Confidence Intervals (CI) for mtDNA common variants, haplogroups, and gene variant burden.

Sources:

  • Glioma Grade and Mortality In Relation To Sequence Variation In the Mitochondrial Genome, Cancer Genetics, 2025;294:171-180
  • Memorial Sloan-Kettering Cancer Center, Department of Epidemiology and Biostatistics, New York, NY 10017, United States
  • National Institutes of Health (NIH) - USA
  • NIH National Cancer Institute (NCI)

Read more